These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study. Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896 [TBL] [Abstract][Full Text] [Related]
5. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832 [TBL] [Abstract][Full Text] [Related]
6. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study. Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837 [TBL] [Abstract][Full Text] [Related]
8. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Yamamoto Y; Nishiyama Y; Kimura N; Ishikawa S; Okuda M; Bandoh S; Kanaji N; Asakura M; Ohkawa M Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):236-45. PubMed ID: 17909790 [TBL] [Abstract][Full Text] [Related]
9. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Yang W; Zhang Y; Fu Z; Yu J; Sun X; Mu D; Han A Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1291-9. PubMed ID: 20309686 [TBL] [Abstract][Full Text] [Related]
10. 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. Yamamoto Y; Nishiyama Y; Ishikawa S; Gotoh M; Bandoh S; Kanaji N; Asakura M; Ohkawa M J Comput Assist Tomogr; 2008; 32(3):432-7. PubMed ID: 18520552 [TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of imaging proliferative activity in lung nodules. Buck AK; Hetzel M; Schirrmeister H; Halter G; Möller P; Kratochwil C; Wahl A; Glatting G; Mottaghy FM; Mattfeldt T; Neumaier B; Reske SN Eur J Nucl Med Mol Imaging; 2005 May; 32(5):525-33. PubMed ID: 15599526 [TBL] [Abstract][Full Text] [Related]
12. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions? Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207 [TBL] [Abstract][Full Text] [Related]
13. Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis. Shen G; Ma H; Pang F; Ren P; Kuang A Acta Radiol; 2018 Feb; 59(2):188-195. PubMed ID: 28475024 [TBL] [Abstract][Full Text] [Related]
14. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617 [TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET. Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872 [TBL] [Abstract][Full Text] [Related]
16. [18F]FLT PET for diagnosis and staging of thoracic tumours. Dittmann H; Dohmen BM; Paulsen F; Eichhorn K; Eschmann SM; Horger M; Wehrmann M; Machulla HJ; Bares R Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1407-12. PubMed ID: 12898201 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging. Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487 [TBL] [Abstract][Full Text] [Related]